VivoSeq
Other

Lymphedema

24

Pipeline Programs↗

7

Active Trials↗

10

Companies Involved↗

Lymphedema is an emerging landscape with 24 programs across 10 companies. The most active players are Microvascular Therapeutics, LLC, Herantis Pharma Plc., Eiger BioPharmaceuticals. 1 therapy is approved with 2 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

50/100

Pipeline Velocity

15/100

Mech. Concentration

14/100

Completion Rate

73/100

Attrition Rate

18/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

M

Microvascular Therapeutics, LLC

1 program

Phase 1H

Herantis Pharma Plc.

1 program

Phase 2E

Eiger BioPharmaceuticals

1 program

Phase 2Novartis logo

Novartis

1 program

Phase 2V

Validus Pharmaceuticals

1 program

Phase 2K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

92%

Small molecule

23 of 25 classified programs — the dominant modality here.

8%ALL OTHERSMonoclonal antibody14%Protein / enzyme14%

Small molecule leads; the ring shows all 25 classified programs, each share of the total. Modality classified for 100% of 26 pipeline programs.

Analysis

Trial Status

33

clinical trials

Completed16 · 48%
Terminated6 · 18%
Recruiting5 · 15%
Unknown status4 · 12%
Active, not recruiting1 · 3%
Enrolling by invitation1 · 3%

Clinical Trials

Trial Activity

33 trials

Systemic Therapy of Open-label Prophylactic Pravastatin or Pentoxifylline/Tocopherol Prevention of Lymphedema Advancing to Eventual Fibrosis: an Interventional Registry-embedded Bayesian Randomized Trial for Radiation Sequelae (STOP4-LATE-FIBROSE)
Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06494111·295 enrolled
Efficacy of GLP-1 Receptor Agonists in Treating Upper and Lower Extremity Lymphedema
Recruiting·AAdvanced Reconstructive Surgery Alliance·Phase 1·NCT07012642·110 enrolled
Clinical Lymphedema Evaluation - Advancing Reconstruction of Head and Neck Lymphatics With Symani
Recruiting·MMMI (Medical Microinstruments, Inc.)·Preclinical·NCT07311876·30 enrolled
Effects of Scapulothoracic Stabilization and Postural Training Added to Standard Lymphedema Care on Muscle Strength, Posture and Functional Outcomes in Secondary Upper Extremity Lymphedema: A Single-Center Randomized Controlled Trial
Recruiting·Toros University·Preclinical·NCT07697495·60 enrolled
Screening for Edema and Breast Cancer-Related Lymphedema in Patients Undergoing Targeted Therapy for Breast Cancer
Recruiting·MMassachusetts General Hospital·N/A·NCT05142800·261 enrolled
Trial of Acebilustat for the Treatment of Upper Arm Lymphedema
Active, not recruiting·SStanford University·Phase 2·NCT05203835·40 enrolled
Sub-Hertz Analysis of Viscoelasticity of Limbs in Patients With Lymphedema
Enrolling by invitation·MMayo Clinic·Preclinical·NCT04258319·90 enrolled
Lipid Peroxidation and Options Antioxidant Therapy for Secondary Lymphedema of the Lower Extremities
Completed·RRyazan State Medical University·Phase 4·NCT04360889·120 enrolled
Lymphatic and Systemic Immunity Changes in Post-radiation Lymphedema Development
Completed·TThe University of Texas Health Science Center, Houston·Phase 1·NCT02949726·80 enrolled
Clinical Study With Lymfactin® in the Treatment of Patients With Secondary Lymphedema (AdeLE)
Completed·HHerantis Pharma Plc.·Phase 2·NCT03658967·39 enrolled
A 24 Month Study to Compare Efficacy of Doxycycline vs Placebo for Improving Filarial Lymphedema in Sri Lanka
Completed·TThe Task Force for Global Health·Phase 3·NCT02929134·219 enrolled
Pycnogenol for the Treatment of Lymphedema
Completed·UUniversity of Wisconsin, Madison·Phase 2·NCT00214032·2 enrolled
Horse Chestnut Seed Extract for Lymphedema
Completed·UUniversity of Wisconsin, Madison·Phase 2·NCT00213928·56 enrolled
A 24 Month Study to Compare Efficacy of Doxycycline vs Placebo for Improving Filarial Lymphedema in India
Completed·TThe Task Force for Global Health·Phase 3·NCT02929121·235 enrolled
Lymphedema Study for Arm or Leg Lymphedema
Completed·SStanford University·Phase 4·NCT02257970·117 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)